Previous Article | Next Article 
Journal of Clinical Microbiology, January 1999, p. 39-44, Vol. 37, No. 1
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Heterogeneously Vancomycin-Resistant Staphylococcus
epidermidis Strain Causing Recurrent Peritonitis in a Dialysis
Patient during Vancomycin Therapy
Krzysztof
Sieradzki,1
Richard B.
Roberts,1,2
David
Serur,2
Judie
Hargrave,2 and
Alexander
Tomasz1,*
Laboratory of Microbiology, The Rockefeller
University, New York, New York 10021,1 and
The New York Hospital-Cornell Medical Center, New York, New
York 100212
Received 20 July 1998/Returned for modification 31 August
1998/Accepted 21 October 1998
 |
ABSTRACT |
Methicillin-resistant Staphylococcus epidermidis (MRSE)
was recovered over a 2-month period from the dialysis fluid of a
peritoneal dialysis (PD) patient who experienced recurrent episodes of
peritonitis during therapeutic and prophylactic use of vancomycin.
Characterization of five consecutive MRSE isolates by molecular and
microbiological methods showed that they were representatives of a
single strain, had reduced susceptibility to vancomycin, did not react
with DNA probes specific for the enterococcal vanA or
vanB gene, and showed characteristics reminiscent of the
properties of a recently described vancomycin-resistant laboratory
mutant of Staphylococcus aureus. Cultures of these MRSE
isolates were heterogeneous: they contained
with a frequency of
10
4 to 10
5
bacteria for which vancomycin
MICs were high (25 to 50 µg/ml) which could easily be selected to
"take over" the cultures by using vancomycin selection in the
laboratory. In contrast, the five consecutive MRSE isolates recovered
from the PD patient during virtually continuous vancomycin therapy
showed no indication for a similar enrichment of more resistant
subpopulations, suggesting the existence of an "occult" infection
site in the patient (presumably at the catheter exit site) which was
not accessible to the antibiotic.
 |
INTRODUCTION |
With the global spread of
methicillin-resistant strains, glycopeptide antibiotics have become
the mainstay of chemotherapy in both coagulase-negative
staphylococci as well as Staphylococcus aureus infections
worldwide. Loss of the antistaphylococcal efficacy of this family of
drugs would pose a serious challenge to the treatment of
methicillin-resistant S. aureus (MRSA)
infections. Such a situation may emerge by the transfer of enterococcal
glycopeptide resistance genes to staphylococci, which often cocolonize
wound infection sites with enterococci. In fact, transfer of the
vancomycin resistance from Enterococcus faecalis to an
S. aureus strain has already been demonstrated under
simulated laboratory conditions (11). An additional concern
relates to the increasingly frequent detection of coagulase-negative
staphylococcal isolates with reduced susceptibility to glycopeptide
antibiotics in clinical specimens associated with a variety of clinical
diseases, particularly in patients undergoing continuous ambulatory
peritoneal dialysis (CAPD) (8, 13-15). Clinical failure of
vancomycin therapy in an MRSA-infected patient has already been
described in Japan (9). Soon after that, MRSA infections for
which the vancomycin MICs showed a similar range (~8 µg/ml) were
also reported in the United States (2, 3).
In this communication, we describe the characterization of five
consecutive isolates of a single methicillin-resistant
Staphylococcus epidermidis (MRSE) strain with reduced
susceptibility to vancomycin and teicoplanin, recovered from the
dialysate of a peritoneal dialysis (PD) patient who experienced
recurrent episodes of peritonitis during an extended period of
therapeutic and/or prophylactic use of vancomycin. Ominously, the PD
catheter site (as well as several other body sites) of the patient was
also colonized by a vancomycin-resistant E. faecalis
strain carrying the vanA gene. Nevertheless, the MRSE isolates did not react with the vanA DNA probe but appeared
to carry a distinct glycopeptide resistance mechanism. The vancomycin MICs for the five MRSE isolates, as determined by broth dilution, were
in the range of 2 to 16 µg/ml. However, population analysis showed
that cultures also contained bacteria for which the vancomycin MICs
were as high as 25 and 50 µg/ml at significant frequencies (10
4 to 10
5). Enrichment for these
subpopulations occurred without difficulty under laboratory conditions.
 |
MATERIALS AND METHODS |
Bacterial strains were grown in tryptic soy broth (TSB; Difco,
Detroit, Mich.) at 37°C with aeration. Organisms were identified to
the species level by the API test system (bioMerieux Vitek, Inc.,
Hazelwood, Mo.). A preliminary determination of MICs of vancomycin was
performed by a broth microdilution method, with TSB (Difco) and
incubation of samples at 37°C for 24 and 48 h. The vancomycin
(and methicillin)-susceptible S. aureus strain NCTC 8325 was
always used as a susceptible control. Population analysis profiles
(PAPs) were done for a more accurate and quantitative evaluation of
antibiotic susceptibility (19). Overnight cultures of
bacteria (
109 CFU/ml) were plated at a series of
dilutions on tryptic soy agar plates containing antibiotic-free medium
or twofold dilutions of the test antibiotic within the drug
concentration range of 0.75 µg up to 100 µg/ml in the cases of
vancomycin and teicoplanin and up to 800 µg/ml in the case of
methicillin. Plates were incubated at 37°C for 48 h, and the
number of bacterial colonies was counted. Plotting colony counts
against drug concentrations provides a graphic display (PAP) of the
composition of the bacterial culture in terms of the homogeneity or
heterogeneity of the antibiotic susceptibility phenotype. Methicillin
and glycopeptide MICs for the majority and for subpopulations of cells
were determined by inspection of PAPs.
Preparation of chromosomal DNA for pulsed-field gel
electrophoresis (PFGE) and separation of
SmaI-restricted fragments in a contour-clamped homogeneous
electric field (CHEF) apparatus (CHEF-DRII; Bio-Rad, Richmond, Calif.)
were carried out as described previously (7). Autolysis was
induced by suspending bacteria in buffer containing Triton X-100
(6). The titer of vancomycin in the growth medium was
determined with a bioassay (16). Aggregation of cells and
the ultrastructure of bacteria were determined by phase-contrast
microscopy and electron microscopy with a procedure previously
described (18).
 |
RESULTS AND DISCUSSION |
Clinical history.
A 34-year-old female first developed renal
failure of unknown etiology in 1985, and by 1988, she required
hemodialysis. Two years later, because of inability to maintain a
vascular access, she was placed on long-term PD. A year later, in 1991, she developed peritonitis, and over the next 6 years, she had recurrent
episodes of peritonitis associated with fever, chills, nausea,
vomiting, and abdominal pain. By 1994, the episodes became more
frequent and severe, and S. epidermidis was first isolated
from cloudy dialysate. She was placed on vancomycin (30 mg per liter)
in each dialysis exchange for 10 to 60 days (5 exchanges per day) when symptoms or cloudy dialysate appeared. S. epidermidis was
frequently recovered from her dialysate prior to each therapeutic
trial. Because of the increasing frequency of her episodes and the need to continue peritoneal dialysis, she was placed on prophylactic vancomycin (30 mg per liter) in each dialysate exchange for 3 weeks of
each month (5 exchanges per day) from January to June of 1997. Because
of the identification of S. epidermidis with intermediate
resistance to vancomycin (Table 1), the
peritoneal dialysis catheter was removed on 16 June 1997, and she was
placed on hemodialysis thrice weekly. Except for one intravenous dose associated with vascular access surgery, she did not receive vancomycin from 16 June until 10 September 1997. During this time period, she felt
well and showed no clinical signs or symptoms of peritonitis, although
she continued to have minimal drainage from the PD catheter site.
Properties of the bacterial isolates.
Table 1 summarizes the
relevant properties of bacteria recovered from a variety of body sites
and the PD fluid. Cultures of peritoneal dialysate collected between 27 March and 28 May yielded pure cultures of MRSE (isolates RR4 through
RR8) with reduced susceptibility to vancomycin and teicoplanin.
Vancomycin-resistant enterococci, consisting of an E. faecium strain (isolate RR1) carrying the
vanB gene and E. faecalis strains (RR2, RR3, and RR9 through RR11) carrying the vanA gene, were also detected
at several body sites of the patient.
PFGE indicated that the five consecutive S. epidermidis
isolates (RR4 through RR8) were identical, and tests with DNA probes specific for the enterococcal vanA (and vanB)
probe showed no hybridization signal (Fig.
1).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 1.
PFGE patterns of isolates recovered from the PD patient.
Chromosomal DNA was prepared, SmaI restricted, and separated
by PFGE (see Materials and Methods). The bottom panel shows results of
hybridization with a probe for vanA. E. faecium strains
EFSK2 (vanB) and EFSK33 (vanA) were used as
controls. l.m.w., low molecular weight.
|
|
Heterogeneity of vancomycin resistance.
Evaluation of the
broth dilution vancomycin MICs for the S. epidermidis
strains after 24 and 48 h of incubation allowed detection of
modest increases in MICs with extended incubation time. A more detailed characterization of overnight cultures of the five
S. epidermidis isolates by population analysis
showed that they were heterogeneous with respect to susceptibility to
vancomycin, teicoplanin, and methicillin (Fig.
2). While the MIC of vancomycin for the majority of cells in these cultures was between 3 and 6 µg/ml, the
cultures also contained bacteria for which the MICs were more substantially increased at low but significant frequencies. For instance, cultures of isolate RR4 contained subpopulations of cells
capable of growing on plates that contained 12 µg of vancomycin per
ml (MIC, 25 µg/ml) at a frequency of 10
4. Cells that
formed colonies on 25 µg of vancomycin per ml (MIC, 50 µg/ml) were
also present (frequency, 10
5).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Phenotypic expression of methicillin (A), vancomycin
(B), and teicoplanin (C) resistance of consecutive isolates of S. epidermidis strains recovered from the PD patient.
|
|
Selection and stability of the highly vancomycin-resistant
subpopulations.
It was relatively easy to increase the proportion
of these subpopulations under laboratory conditions. Colonies of
isolate RR4 that were capable of growing on 6 µg of vancomycin per ml were dispersed in drug-free growth medium and used at very low cell
concentrations (approximately 100 cells per ml) as inocula. Upon
replating for population analysis, the majority of the culture showed
an increase in the vancomycin MIC from 6 µg/ml for the original
isolate, RR4, to 12 µg/ml. A separate colony of RR4 picked from the
25-µg/ml vancomycin plate yielded a culture in which the MIC of
vancomycin shifted up to 25 µg/ml. Both of these cultures also became
more homogeneous with respect to vancomycin susceptibility (Fig.
3A).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 3.
Enrichment of S. epidermidis cultures for
subpopulations of bacteria for which the vancomycin MICs were elevated.
Isolate RR4 was plated for population analysis on agar containing
increasing concentrations of vancomycin ( ). Bacterial cells capable
of forming colonies on the agar containing 6 and 25 µg of
vancomycin/ml (A, 6* and 25*, respectively) were picked, diluted in
drug-free TSB, grown overnight, and subsequently plated for population
analysis. Symbols indicate cultures grown from a colony picked from the
6-µg/ml plate ( ) or from the 25-µg/ml plate ( ). A culture of
RR4 was diluted into TSB con- taining increasing concentrations of vancomycin (eventually
25 µg/ml), grown overnight, and then plated for population analysis
on agar plates containing vancomycin (B) or teicoplanin (C). Open
circles ( ) represent population profiles of the original culture.
|
|
In an additional experiment, a small aliquot of strain RR4 culture was
diluted into TSB containing 6 µg of vancomycin per ml. After
overnight growth, this culture was reinoculated into TSB with 12 µg
of vancomycin per ml and, subsequently, into medium containing 25 µg
of vancomycin per ml. Figure 3B shows that this procedure also resulted
in the selection of the originally minor, highly vancomycin-resistant
subpopulation, which became the major component of the enriched
culture, for which the vancomycin MIC was in the range of 25 to 50 µg/ml. The teicoplanin MIC for the same culture increased from the
original 25 to 50 µg/ml to greater than 100 µg/ml (Fig. 3C). The
elevated MIC for such highly vancomycin-resistant bacteria was retained
during extensive passage (over 70 generations) in drug-free medium.
Enrichment of S. epidermidis cultures for bacteria for
which the vancomycin MIC was increased during exposure to a
bactericidal concentration of the antibiotic.
S. epidermidis
isolates RR4 and RR8 were grown in TSB. At a cell concentration of
about 5 × 106 CFU/ml, both cultures received 30 µg
of vancomycin per ml, and viable titers were determined at hourly
intervals (Fig. 4 [top]). After 7 h of incubation with the antibiotic, the viable titers of the cultures
were reduced to about 5 × 104 and 5 × 103 CFU/ml in strains RR4 and RR8, respectively. The drop
in viability was not accompanied by any change in optical density of
the cultures. Upon further incubation (6 to 7 days), both cultures
increased in viable titer (and optical density), to reach a
stationary-phase concentration of about 5 × 109
CFU/ml. Population analysis done at the beginning and at the end of
this experiment showed increases in the vancomycin MICs from 6 µg/ml
to 50 µg/ml in RR4 and from 3 µg/ml to 25 µg/ml in RR8 (Fig. 4).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 4.
Selection for bacteria with increased vancomycin
resistance during the bactericidal action of vancomycin. (Top panel)
Effect of vancomycin (30 µg/ml added at the time indicated by arrow)
on the viable titers of strains RR4 ( ) and RR8 ( ). (Bottom
panels) Population analysis of the two strains before ( ) and after
( ) the massive population shift caused by vancomycin treatment.
|
|
S. epidermidis isolates (RR4 through RR8) grown in the
presence of one-half of the respective MICs of vancomycin from small inocula in TSB containing the antibiotic showed several properties reminiscent of a highly vancomycin-resistant S. aureus
laboratory mutant, VM (16), and several coagulase-negative
staphylococcal isolates (12, 17) described recently. Thus,
isolates RR4 through RR8 grown from small inocula in the presence of
one-half the respective MICs of vancomycin for them showed the
following. (i) There was aggregation easily visible to the eyes. (ii)
Electron microscopy of RR4 through RR8 grown in the presence of
vancomycin indicated formation of multicellular aggregates and the
production of excess surface material similar in staining properties to
that of cell wall (not shown). (iii) The results of biochemical tests
(not shown) indicated that vancomycin completely inhibited autolysis of
the cultures. (iv) Titration of the supernatants with a bioassay for
free antibiotic showed that each of the cultures was capable of
quantitatively removing vancomycin from the growth medium (data not shown).
These in vitro studies demonstrate unequivocally that the heterogeneous
cultures of isolates RR4 through RR8 represent potential reservoirs of
staphylococci for which the vancomycin MICs are above therapeutically
achievable levels. The ease with which selection of these
subpopulations occurred in the laboratory suggests that such
subpopulations may also emerge in vivo, depending on the pharmacokinetics of vancomycin, the dosage regimen used, and the size
of the pathogen population at the infection site(s). For these reasons,
it was surprising to find that there was no significant upwards shift
in the vancomycin MICs or PAPs among the consecutive surveillance
cultures (RR4 through RR8) recovered from the patient during 2 months
of extensive vancomycin prophylaxis.
The medical records allow one to estimate that between January and June
of 1997, the patient received a total of close to 29 g of
intraperitoneal vancomycin delivered in doses of 3 weeks of continuous
administration per month. Despite this extensive exposure, the same
S. epidermidis strain with a virtually identical hetero-resistance profile to vancomycin was recovered from each of the
five dialysate samples, collected through a 2-month period of extensive
vancomycin prophylaxis.
These observations allow two conclusions. (i) They clearly document
failure of vancomycin prophylaxis to provide bacteriological cure of
the PD infection. (ii) In contrast to the results of the in vitro
studies, the in vivo use of vancomycin did not cause elevation of
vancomycin resistance levels in the isolates, suggesting that the
"core" S. epidermidis culture responsible for the
repeated infections of the patient was not fully accessible to the
antibiotic, most likely because of its localization at the catheter
exit site. Relatively poor access of antibacterial agents to
staphylococci adhering to artificial surfaces affecting reduced
susceptibility to antibiotic killing has been demonstrated repeatedly
(1, 4, 5, 10, 20). In fact, the episodes of recurrent
S. epidermidis peritonitis of the patient described here
only ceased upon subsequent removal of the dialysis catheter.
In view of the concern over the transfer of vancomycin resistance genes
from enterococci to staphylococci under clinical conditions, it was an
ominous sign that the PD catheter site (and several other body sites)
of this patient was, at times, also colonized by vancomycin-resistant
strains of E. faecalis (vanA) and E. faecium (vanB). It is conceivable that the
overproduction of cell walls associated with the staphylococcal
resistance mechanism may serve as a barrier to such interspecific gene
transfers (16).
This report underscores the urgent need to delineate the mechanism(s)
of the unique staphylococcal vancomycin resistance, to continue
surveillance for the possible interspecific transfer of resistance
genes to staphylococci, and to define the role of therapeutic and
prophylactic dosing regimens in the selection of highly
vancomycin-resistant staphylococcal strains.
 |
ACKNOWLEDGMENTS |
Partial support was provided by the Bodman/Achelis Fund, the
Lounsbery Foundation, and the Cary L. Guy Foundation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The Rockefeller
University, Laboratory of Microbiology, 1230 York Ave., New York,
NY 10021. Phone: (212) 327-8277. Fax: (212) 327-8688. E-mail:
tomasz{at}rockvax.rockefeller.edu.
 |
REFERENCES |
| 1.
|
Brown, M. R.,
D. G. Allison, and P. Gilbert.
1988.
Resistance of bacterial biofilms to antibiotics: a growth-rate related effect?
J. Antimicrob. Chemother.
22:777-780[Free Full Text].
|
| 2.
|
Centers for Disease Control and Prevention.
1997.
Staphylococcus aureus with reduced susceptibility to vancomycin United States, 1997.
Morbid. Mortal. Weekly Rep.
46:765-766[Medline].
|
| 3.
|
Centers for Disease Control and Prevention.
1997.
Update: Staphylococcus aureus with reduced susceptibility to vancomycin United States, 1997.
Morbid. Mortal. Weekly Rep.
46:813-815[Medline].
|
| 4.
|
Chuard, C.,
P. E. Vaudaux,
R. A. Proctor, and D. P. Lew.
1997.
Decreased susceptibility to antibiotic killing of a stable small colony variant of Staphylococcus aureus in fluid phase and on fibronectin-coated surfaces.
J. Antimicrob. Chemother.
39:603-608[Abstract/Free Full Text].
|
| 5.
|
Chuard, C.,
P. Vaudaux,
F. A. Waldvogel, and D. P. Lew.
1993.
Susceptibility of Staphylococcus aureus growing on fibronectin-coated surfaces to bactericidal antibiotics.
Antimicrob. Agents Chemother.
37:625-632[Abstract/Free Full Text].
|
| 6.
|
de Jonge, B. L. M.,
H. de Lencastre, and A. Tomasz.
1991.
Suppression of autolysis and cell wall turnover in heterogeneous Tn551 mutants of a methicillin-resistant Staphylococcus aureus strain.
J. Bacteriol.
173:1105-1110[Abstract/Free Full Text].
|
| 7.
|
de Lencastre, H., and A. Tomasz.
1994.
Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus.
Antimicrob. Agents Chemother.
38:2590-2598[Abstract/Free Full Text].
|
| 8.
|
Grant, A. C.,
R. W. Lacey,
A. M. Brownjohn, and J. H. Turney.
1986.
Teicoplanin-resistant coagulase-negative Staphylococcus.
Lancet
ii:1166-1167.
|
| 9.
|
Hiramatsu, K.,
H. Hanaki,
T. Ino,
K. Yabuta,
T. Oguri, and F. C. Tenover.
1997.
Methicillin resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
J. Antimicrob. Chemother.
40:135-136[Free Full Text].
|
| 10.
|
Khardori, N.,
M. Yassien, and K. Wilson.
1995.
Tolerance of Staphylococcus epidermidis grown from indwelling vascular catheters to antimicrobial agents.
J. Ind. Microbiol.
15:148-151[Medline].
|
| 11.
|
Noble, W. C.,
Z. Virani, and R. G. A. Cree.
1992.
Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.
FEMS Microbiol. Lett.
93:195-198.
|
| 12.
|
Sanyal, D., and D. Greenwood.
1993.
An electronmicroscope study of glycopeptide antibiotic-resistant strains of Staphylococcus epidermidis.
J. Med. Microbiol.
39:204-210[Abstract].
|
| 13.
|
Sanyal, D.,
A. P. Johnson,
R. C. George,
B. D. Cookson, and A. J. Williams.
1991.
Peritonitis due to vancomycin-resistant Staphylococcus epidermidis.
Lancet
337:54[Medline].
|
| 14.
|
Sanyal, D.,
A. P. Johnson,
R. C. George,
R. Edwards, and D. Greenwood.
1993.
In-vitro characteristics of glycopeptide resistant strains of Staphylococcus epidermidis isolated from patients on CAPD.
J. Antimicrob. Chemother.
32:267-278[Abstract/Free Full Text].
|
| 15.
|
Schwalbe, R. S.,
J. T. Stapleton, and P. H. Gilligan.
1987.
Emergence of vancomycin resistance in coagulase-negative staphylococci.
N. Engl. J. Med.
316:927-931[Medline].
|
| 16.
|
Sieradzki, K., and A. Tomasz.
1997.
Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.
J. Bacteriol.
179:2557-2566[Abstract/Free Full Text].
|
| 17.
|
Sieradzki, K.,
P. Villari, and A. Tomasz.
1998.
Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci.
Antimicrob. Agents Chemother.
42:100-107[Abstract/Free Full Text].
|
| 18.
|
Tomasz, A.,
J. D. Jamieson, and E. Ottolenghi.
1964.
The fine structure of Diplococcus pneumoniae.
J. Cell Biol.
22:453-467[Abstract/Free Full Text].
|
| 19.
|
Tomasz, A.,
S. Nachman, and H. Leaf.
1991.
Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci.
Antimicrob. Agents Chemother.
35:124-129[Abstract/Free Full Text].
|
| 20.
|
von Graevenitz, A., and D. Amsterdam.
1992.
Microbiological aspects of peritonitis associated with continuous ambulatory peritoneal dialysis.
Clin. Microbiol. Rev.
5:36-48[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, January 1999, p. 39-44, Vol. 37, No. 1
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Carmen, J. C., Roeder, B. L., Nelson, J. L., Beckstead, B. L., Runyan, C. M., Schaalje, G. B., Robison, R. A., Pitt, W. G.
(2004). Ultrasonically Enhanced Vancomycin Activity Against Staphylococcus Epidermidis Biofilms in Vivo. J Biomater Appl
18: 237-245
[Abstract]
-
Van Der Zwet, W. C., Debets-Ossenkopp, Y. J., Reinders, E., Kapi, M., Savelkoul, P. H. M., Van Elburg, R. M., Hiramatsu, K., Vandenbroucke-Grauls, C. M. J. E.
(2002). Nosocomial Spread of a Staphylococcus capitis Strain with Heteroresistance to Vancomycin in a Neonatal Intensive Care Unit. J. Clin. Microbiol.
40: 2520-2525
[Abstract]
[Full Text]
-
Biavasco, F., Vignaroli, C., Lazzarini, R., Varaldo, P. E.
(2000). Glycopeptide Susceptibility Profiles of Staphylococcus haemolyticus Bloodstream Isolates. Antimicrob. Agents Chemother.
44: 3122-3126
[Abstract]
[Full Text]
-
Villari, P., Sarnataro, C., Iacuzio, L.
(2000). Molecular Epidemiology of Staphylococcus epidermidis in a Neonatal Intensive Care Unit over a Three-Year Period. J. Clin. Microbiol.
38: 1740-1746
[Abstract]
[Full Text]